It is often broken down into two separate subcomponents which comprise this effect: The first of these components involves the self-regulation of attention so that its focus is completely directed towards immediate experience, thereby quietening one's internal narrative and allowing for increased recognition of external and mental events within the present moment. The second of these components involves adopting a particular orientation toward one’s experiences in the present moment that is characterized by a lack of judgement, curiosity, openness, and acceptance.
Within meditation, this state of mind is deliberately practised and maintained via the conscious and manual redirection of one's awareness towards a singular point of focus for extended periods of time. However, within the context of psychoactive substance usage, this state is often spontaneously induced without any conscious effort or the need of any prior knowledge regarding meditative techniques.
Mindfulness is often accompanied by other coinciding effects such as anxiety suppression and focus enhancement. It is most commonly induced under the influence of moderate dosages of hallucinogenic compounds, such as psychedelics, dissociatives, and cannabinoids. However, it can also occur on entactogens, certain nootropics such as l-theanine, and during simultaneous doses of benzodiazepines and stimulants.
Compounds within our psychoactive substance index which may cause this effect include:
- Phenethylamine (compound)
- Psilocybin mushrooms
Anecdotal reports which describe this effect within our experience index include:
- Experience: 36mg 4-AcO-DiPT - Truly, one for the psychedelic animals among us
- Experience: 5-EAPB (60mg) + 2-FMA (20mg) + 4-AcO-DMT (10mg) - Emotional catharsis
- Experience:100-350mg - Phenylpiracetam in daily life
- Experience:120µg LSD - First Bad Acid Trip, Psychosis
- Experience:2.5g Syrian rue + 6g Mimosa Hostilis - My first experience with unity
- Experience:225mg Pregabalin +Cannabis -Bliss and Serenity; a hedonistic evening
- Experience:3 Grams of Mushrooms - Reset on my Life, Experiencing Satori and the Cosmic Perspective
- Experience:60mg 4-AcO-DMT Nonstop Quasi-Orgasmic Objectless Euphoria
- Experience:BK-2C-B - Various experiences
- Experience:Mushrooms (~0.5 g) - Autonomous Voice
- Experience:Mushrooms and Snuff Films -- Trip Report (3.5 grams)
- Experience:Psilocybin Mushroom (0.16 g, Oral) - Dosage Independent Intensity
- Responsible use
- Subjective effects index
- Psychedelics - Subjective effects
- Dissociatives - Subjective effects
- Deliriants - Subjective effects
- Slagter, H. A., Davidson, R. J., Lutz, A. (2011). "Mental Training as a Tool in the Neuroscientific Study of Brain and Cognitive Plasticity". Frontiers in Human Neuroscience. 5. doi:10.3389/fnhum.2011.00017. ISSN 1662-5161.
- Pagnini, F., Philips, D. (April 2015). "Being mindful about mindfulness". The Lancet Psychiatry. 2 (4): 288–289. doi:10.1016/S2215-0366(15)00041-3. ISSN 2215-0366.
- Baer, R. A. (2003). "Mindfulness training as a clinical intervention: A conceptual and empirical review". Clinical Psychology: Science and Practice. 10 (2): 125–143. doi:10.1093/clipsy.bpg015. ISSN 1468-2850.
- Creswell, J. D. (3 January 2017). "Mindfulness Interventions". Annual Review of Psychology. 68 (1): 491–516. doi:10.1146/annurev-psych-042716-051139. ISSN 0066-4308.
- Bishop, S. R., Lau, M., Shapiro, S., Carlson, L., Anderson, N. D., Carmody, J., Segal, Z. V., Abbey, S., Speca, M., Velting, D., Devins, G. (2004). "Mindfulness: A proposed operational definition". Clinical Psychology: Science and Practice. 11 (3): 230–241. doi:10.1093/clipsy.bph077. ISSN 1468-2850.